Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina
暂无分享,去创建一个
D. Bates | J. Bainbridge | N. Ved | L. Donaldson | R. Hulse | S. Bestall
[1] Jules C Hancox,et al. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. , 2017, ACS chemical biology.
[2] D. Bates,et al. Altered ratios of pro‐ and anti‐angiogenic VEGF‐A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma , 2016, Journal of Pathology.
[3] Noemi Lois,et al. The progress in understanding and treatment of diabetic retinopathy , 2016, Progress in Retinal and Eye Research.
[4] S. Harper,et al. Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. , 2015, Clinical science.
[5] G. Damodaran,et al. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[6] J. Oxley,et al. SERINE ARGININE PROTEIN KINASE-1 (SRPK1) INHIBITION AS A POTENTIAL NOVEL TARGETED THERAPEUTIC STRATEGY IN PROSTATE CANCER , 2014, Oncogene.
[7] D. Bates,et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma , 2014, British Journal of Cancer.
[8] S. Harper,et al. TNF-α-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation , 2014, Molecular vision.
[9] Ian Y. Wong,et al. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications , 2014, Diabetes Care.
[10] R. Simó,et al. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy , 2014, Diabetes Care.
[11] P. Kehoe,et al. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. , 2013, The American journal of pathology.
[12] S. Harper,et al. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. , 2013, Investigative ophthalmology & visual science.
[13] C. L. Schlamp,et al. Evaluation of the percentage of ganglion cells in the ganglion cell layer of the rodent retina , 2013, Molecular vision.
[14] K. Falavarjani,et al. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature , 2013, Eye.
[15] D. Antonetti,et al. Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. , 2012, The Biochemical journal.
[16] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[17] M. Ladomery,et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.
[18] Min Zhao,et al. Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy. , 2011, Experimental eye research.
[19] T. Kern,et al. Inflammation in diabetic retinopathy , 2011, Progress in Retinal and Eye Research.
[20] Yuan-Yuan Shi,et al. Influence of Dll4 via HIF-1α-VEGF Signaling on the Angiogenesis of Choroidal Neovascularization under Hypoxic Conditions , 2011, PloS one.
[21] J. Tang,et al. Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop , 2010, Molecular vision.
[22] S. Harper,et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularization. , 2010, Investigative ophthalmology & visual science.
[23] S. Harper,et al. VEGF-A165b is cytoprotective and antiangiogenic in the retina. , 2010, Investigative ophthalmology & visual science.
[24] D. Bates. Vascular endothelial growth factors and vascular permeability , 2010, Cardiovascular research.
[25] Cristina Hernández,et al. The Retinal Pigment Epithelium: Something More than a Constituent of the Blood-Retinal Barrier—Implications for the Pathogenesis of Diabetic Retinopathy , 2010, Journal of biomedicine & biotechnology.
[26] Magali Saint-Geniez,et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris , 2009, Proceedings of the National Academy of Sciences.
[27] M. Gent,et al. A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding , 2008 .
[28] Steven J. Harper,et al. VEGF-A splicing: the key to anti-angiogenic therapeutics? , 2008, Nature Reviews Cancer.
[29] Lars Jakobsson,et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. , 2008, Blood.
[30] M. Ladomery,et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors , 2008, Journal of Cell Science.
[31] A. Barber,et al. Retinal ganglion cells in diabetes , 2008, The Journal of physiology.
[32] Maryam Hamdollah-Zadeh,et al. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. , 2008, European journal of cancer.
[33] C. Scholfield,et al. Diabetes Downregulates Large-Conductance Ca2+-Activated Potassium &bgr;1 Channel Subunit in Retinal Arteriolar Smooth Muscle , 2007, Circulation research.
[34] Antonio Duarte,et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching , 2007, Proceedings of the National Academy of Sciences.
[35] Holger Gerhardt,et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.
[36] T. Gardner,et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. , 2006, Investigative ophthalmology & visual science.
[37] S. Harper,et al. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. , 2006, Molecular vision.
[38] S. Harper,et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor , 2005, Diabetologia.
[39] H. Hammes,et al. Pericytes and the Pathogenesis of Diabetic Retinopathy , 2005, Diabetes.
[40] Marina Ziche,et al. VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.
[41] Ulrich Schraermeyer,et al. A central role for inflammation in the pathogenesis of diabetic retinopathy , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[43] K. Yamashiro,et al. VEGF164 is proinflammatory in the diabetic retina. , 2003, Investigative ophthalmology & visual science.
[44] T. Gardner,et al. Diabetic retinopathy: more than meets the eye. , 2002, Survey of ophthalmology.
[45] L. Aiello,et al. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. , 2002, Ophthalmology.
[46] Cristina Hernández,et al. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. , 2002, American journal of ophthalmology.
[47] D. Gillatt,et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. , 2002, Cancer research.
[48] G. Yancopoulos,et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. , 2002, The Journal of clinical investigation.
[49] G. Yancopoulos,et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. , 2001, Investigative ophthalmology & visual science.
[50] C Bellman,et al. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. , 2001, Investigative ophthalmology & visual science.
[51] A. Adamis,et al. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. , 2001, Investigative ophthalmology & visual science.
[52] K. Jin,et al. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] Michael H. Goldbaum,et al. Measurement and classification of retinal vascular tortuosity , 1999, Int. J. Medical Informatics.
[54] J. Melia,et al. Why some cases of retinopathy worsen when diabetic control improves , 1997, BMJ.
[55] S. Bursell,et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. , 1996, Investigative ophthalmology & visual science.
[56] D. Weinberger,et al. Non-retinovascular leakage in diabetic maculopathy. , 1995, The British journal of ophthalmology.
[57] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[58] K. Dahl-Jørgensen,et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. , 1985, British medical journal.
[59] J. Cunha-Vaz. The blood-retinal barriers , 1976, Documenta Ophthalmologica.
[60] J. Cunha-Vaz,et al. Studies on the permeability of the blood-retinal barrier. IV. Junctional complexes of the retinal vessels and their role in the permeability of the blood-retinal barrier. , 1966, Experimental eye research.
[61] D TOUSSAINT,et al. Retinal vascular patterns. IV. Diabetic retinopathy. , 1961, Archives of ophthalmology.
[62] J. Folkman,et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. , 1995, Molecular medicine.
[63] J. Folkman,et al. Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen , 1995 .
[64] Photocoagulation therapy for diabetic eye disease. Early Treatment Diabetic Retinopathy Study Research Group. , 1985, JAMA.
[65] R. Klein,et al. Visual impairment in diabetes. , 1984, Ophthalmology.